Pharmafile Logo
Pharmafocus logo
Advanced Search

MSD

Showing 15 posts of 247 posts found.

shutterstock_273326141

MSD scoops up biopharma firm Tilos for $773 million

June 10, 2019
Sales and Marketing MSD, Tilos Therapeutics, acquisition, pharma

US-based firm MSD has announced it intends to acquire biopharma firm Tilos Therapeutics, and has signed a deal with the …

News
merckentranceweb

Longest follow up trial of Merck’s Keytruda sets new standard for five year survival in lung cancer

June 3, 2019
Sales and Marketing KEYNOTE, MSD, Merck, keytruda, lung cancer

Nearly a quarter of previously untreated lung cancer patients who took Keytruda (Pembrolizumab) were alive after five years, according to …

News
merckwindow_web

NICE recommends MSD’s Prevymis for CMV prevention following allogeneic haematopoietic stem cell transplant

May 31, 2019
Medical Communications, Sales and Marketing MSD, NICE, Prevymis, UK, cmv, cytomegalovirus, pharma

MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

May 24, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten

On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …

News
merckwindow_web

MSD buys Peloton Therapeutics in deal worth $2.1 billion

May 22, 2019
Research and Development Cancer, MSD, acquisition, biotech, deal, oncology, pharma

MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion. US …

News
merck-keytruda

Keytruda fails to improve overall survival in advanced triple-negative breast cancer

May 21, 2019
Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma, triple-negative breast cancer

MSD has made it known that its cancer immunotherapy Keytruda (pembrolizumab) failed to meet its primary endpoint in a Phase …

News
merck-keytruda

MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma

May 14, 2019
Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma

MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …

News
credit_-_daniel_leal-olivas-afp

AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer

April 29, 2019
Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …

News
dw-anzcxqaqavhl

FDA approves Beximco’s generic version of MSD’s allergy drug Periactin

April 25, 2019
Sales and Marketing FDA, MSD, Periactin, allergy, generics, pharma

Bangladesh-based Beximco Pharma is celebrating following the decision from the FDA to approve its generic version of MSD’s antihistamine therapy …

News
merck-keytruda

Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer

April 23, 2019
Manufacturing and Production, Sales and Marketing FDA, MSD, Pfizer, Sutent, inlyta, keytruda, pharma

MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination …

News
merckwindow_web

FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer

April 12, 2019
Medical Communications, Research and Development Cancer, MSD, keytruda, lung cancer, non-small cell lung cancer, pharma

MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …

News
lynparza

Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer

April 10, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma

Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …

News
merckwindow_web

China approves Keytruda for non-small cell lung cancer

April 2, 2019
Manufacturing and Production China, MSD, Merck and Co, USA, keytruda, lung cancer, pharma

US firm MSD has won approval for Keytruda in China. The cancer immunotherapy has thus become the first PD-1 inhibitor …

News
merckwindow_web

MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer

March 15, 2019
Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025